Cancer News and Research

RSS

Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.

Study Unveils How Bacteria Thrive Within the Nucleus of Deep-Sea Mussels

Most animals live in intimate relationships with bacteria. Some of these bacteria live inside the cells of their hosts, but only very few are able to live inside cell organelles (structures inside the cell, like organs in the body).

9 Sep 2024

Crystal Structure of i-Motif DNA Opens Doors for Targeted Drug Design

The first crystal structure of an alternative DNA shape from the insulin gene has been revealed by a UCL-led research team.

9 Sep 2024

A New Approach to Understanding Enhancer-TF Interactions

Every cell in the human body has the same DNA, yet liver cells differ from brain cells, and skin cells from muscle cells.

9 Sep 2024

Breakthrough Nanoparticle Therapy Boosts Immune Response Against Aggressive Pancreatic Cancer

Innovative use of lipid nanoparticles to deliver immune agonists shows promise in activating anti-tumor immunity in pancreatic ductal adenocarcinoma models.

9 Sep 2024

Common Skin Fungus Identified as a Potential Factor in Tumor Growth

A common skin fungus, Malassezia globosa may invade deep tissues through the skin or by other means, then cause tumor growth, according to a new study.

6 Sep 2024

Fish Gut Bacteria May Hold the Key to New Skincare Ingredients

There are some pretty strange ingredients in cosmetics and skin care products. One example is snail mucin -; also known as snail slime -; which is used for its moisturizing and antioxidant properties.

6 Sep 2024

AMLo Biosciences Receives UKCA Mark for Groundbreaking Melanoma Biomarker Test

AMLo Biosciences Ltd (Newcastle upon Tyne, UK) announces the successful receipt of the UKCA mark for AMBLor. AMBLor is a groundbreaking histopathological biomarker test for the personal identification of early-stage melanomas at low risk of progression, post staging diagnosis.

6 Sep 2024

Fruit Fly Study Reveals New Mechanism for Protein Production

Scientists from the University of California, Merced discovered a biological mechanism shared by numerous creatures through the use of fruit flies, which could have a significant influence on the comprehension of cancer and aging.

5 Sep 2024

Rice Researchers Map Protein Interactions for Creating Functional Gas Vesicles

As far as water gear goes, floaties are not exactly high tech. But the tiny air-filled bubbles some microorganisms use as flotation devices when they compete for light on the water surface are a different story.

4 Sep 2024

Researchers Uncover Hundreds of New Potential Cancer Driver Genes

Researchers at the Centre for Genomic Regulation (CRG) have discovered hundreds of potential new cancer driver genes.

4 Sep 2024

Inflammation-Induced Epigenetic Changes Limit Intestinal Stem Cell Regeneration

Researchers from the University of Michigan, Baylor College of Medicine, and other affiliated institutions have found that intestinal stem cells (ISCs) are permanently altered by inflammation in the gut, which limits the cells' capacity to repair the gut even after the inflammation has subsided.

4 Sep 2024

New Advances in DEL Technology Facilitate Synthesis of Large, Complex Molecules

These days, remarkable new medical treatments are all the rage. One such treatment is personalized cancer therapy, which uses antibodies or immune cells that have been altered.

4 Sep 2024

Alternative Splicing Shapes Biological Complexity through Gene Expression Modulation

A genetic process known as “alternative splicing” involves cutting out specific gene segments and joining the remaining segments to form messenger RNA (mRNA) during transcription.

4 Sep 2024

Study Reveals Cytoskeleton as Key Component in Aging Dermal Fibroblasts

A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 16 on August 27, 2024, entitled, "Proteomic and secretomic comparison of young and aged dermal fibroblasts highlights cytoskeleton as a key component during aging."

4 Sep 2024

CRISPR/Cas System Revolutionizes Tumor Variant and Biomarker Detection

The CRISPR-Cas system is transforming tumor biomarker detection, enabling ultra-sensitive diagnostics and improving accuracy in cancer detection and monitoring.

4 Sep 2024

Melbourne Researchers Achieve Breakthrough in Creating Human-Like Blood Stem Cells

Melbourne researchers have made a world first breakthrough into creating blood stem cells that closely resemble those in the human body.

3 Sep 2024

Arctic Actinobacteria Yield Novel Antivirulence Compounds Against E. coli

A novel set of techniques was created by researchers in Finland and Norway to screen unknown substances with bacterial origin for antivirulence activity.

2 Sep 2024

European Commission Approves Erdafitinib for Advanced Urothelial Carcinoma

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved BALVERSA®▼(erdafitinib) as a once-daily oral monotherapy for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (mUC), harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations who have previously received at least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor in the unresectable or metastatic treatment setting.

30 Aug 2024

RYBREVANT Receives EC Nod for Advanced Lung Cancer Treatment

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved a Type II extension of indication for RYBREVANT®▼ (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed), for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (ex19del) or Exon 21 L858R substitution (L858R) mutations, after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).

30 Aug 2024